Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Jill Piens"'
1
Akademický článek
A five arm natural history study of nasal vestibulitis
Autor: Elizabeth J. Cathcart‐Rake, David Zahrieh, Deanne Smith, Susan Young, Shaylene McCue, Amanda O'Connor, Stephan Thomé, Mario Lacouture, Terra Register, Jill Piens, Bret B. Friday, Charles L. Loprinzi
Publikováno v: Cancer Medicine, Vol 12, Iss 8, Pp 9650-9654 (2023)
Abstract Introduction Nasal symptoms are frequently reported by patients undergoing chemotherapy. Methods Eligible patients planning to receive paclitaxel, docetaxel, nab‐paclitaxel, bevacizumab without a concomitant taxane, or “other” (non‐t
Externí odkaz: https://doaj.org/article/eef6427d42514b0c9fd6e63b398eebf1
Zobrazit plný text záznamu
2
Natural history of nasal vestibulitis associated with paclitaxel, docetaxel, and other chemotherapy agents: a Minnesota Cancer Clinical Trials Network (MNCCTN) study
Autor: Mario E. Lacouture, Bret Edward Buckley Friday, Stephan D. Thomé, Jill Piens, Amanda O’Connor, Charles L. Loprinzi, David Zahrieh, Deanne Smith, Terra Register, Shaylene A. McCue, Susan Young, Elizabeth J. Cathcart-Rake
Publikováno v: Supportive Care in Cancer. 29:6253-6258
To describe the natural history of nasal vestibulitis in patients receiving taxane chemotherapy, including incidence, severity, and associated symptoms. Eligible patients with minimal or no baseline nasal symptoms were enrolled in this natural histor
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f2fc5f7b3d8045aa0566e98b7fad0058
https://doi.org/10.1007/s00520-021-06190-0
Zobrazit plný text záznamu
3
Natural history of nasal vestibulitis associated with paclitaxel, docetaxel, and other chemotherapy agents: a Minnesota Cancer Clinical Trials Network (MNCCTN) study
Autor: Elizabeth J, Cathcart-Rake, David, Zahrieh, Deanne, Smith, Susan, Young, Shaylene, McCue, Amanda, O'Connor, Stephan, Thomé, Mario, Lacouture, Terra, Register, Jill, Piens, Bret B, Friday, Charles L, Loprinzi
Publikováno v: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 29(11)
To describe the natural history of nasal vestibulitis in patients receiving taxane chemotherapy, including incidence, severity, and associated symptoms.Eligible patients with minimal or no baseline nasal symptoms were enrolled in this natural history
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f8a6d2870d2c4434c702cae18047b53f
https://pubmed.ncbi.nlm.nih.gov/33851235
Zobrazit plný text záznamu
4
Nasal vestibulitis: An MNCCTN natural history trial—Nasal vestibulitis symptoms associated with paclitaxel, docetaxel, and other chemotherapy agents
Autor: David Zahrieh, Charles L. Loprinzi, Terra Register, Shaylene A. McCue, Eric G. Wolfe, Stephan D. Thomé, Susan Young, Jill Piens, Elizabeth J. Cathcart-Rake, Amanda O’Connor, Mario E. Lacouture, Deanne s. Smith
Publikováno v: Journal of Clinical Oncology. 38:e24086-e24086
e24086 Background: Nasal vestibulitis has been infrequently described as a side effect of cancer-directed therapy; however, a preliminary study reported that 71% of patients undergoing taxane chemotherapy experienced nasal vestibulitis symptoms. This
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::75f5a86b71fefca0499c25d31ee4a634
https://doi.org/10.1200/jco.2020.38.15_suppl.e24086
Zobrazit plný text záznamu
5
Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points
Autor: Crescent R. Isham, Jeff A. Sloan, Matthew M. Ames, Alex A. Adjei, Scott H. Kaufmann, Stacie L. Rubin, Jill Piens, Pamela J. Atherton, Keith C. Bible, Michelle K. Daiss, Janet Lensing, Sacha A. Nelson, Charles Erlichman, Joseph Rubin, Joel M. Reid, Yean K. Lee
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 11(16)
Purpose: Flavopiridol, a cyclin-dependent kinase inhibitor, transcription inhibitor, and DNA-interacting agent, was combined with cisplatin or carboplatin to establish toxicities, evaluate pharmacokinetics, and examine its effects on patient cancers
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98aad935af1432f6f6517da47e67b8e2
https://pubmed.ncbi.nlm.nih.gov/16115936
Zobrazit plný text záznamu
6
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies
Autor: Keri Van Becelaere, Jill Piens, Judith Sebolt-Leopold, Roman Herrera, David Y. Mitchell, Laura M. Bruzek, Alex A. Adjei, Patricia M. LoRusso, Peggy Asbury, Lorelei J. Hanson, Mark B. Meyer, Pamela DeLuca, Joel M. Reid, Shirish Gadgeel, Mary Varterasian
Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(23)
Purpose This phase I study was undertaken to define the toxicity, pharmacokinetics, pharmacodynamics, maximum tolerated dose (MTD), and clinical activity of CI-1040, a small-molecule inhibitor of the dual-specificity kinases MEK(mitogen-activated pro
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0e4d6a635605ebbfcc567b3ad9e01a2
https://pubmed.ncbi.nlm.nih.gov/16009947
Zobrazit plný text záznamu
8
A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM)
Autor: Araba A. Adjei, Heather A. Wakelee, J. D. Dugay, Joel M. Reid, Jill Piens, Janet Lensing, Branimir I. Sikic, Joanne Halsey, Lorelei J. Hanson
Publikováno v: Journal of Clinical Oncology. 24:3044-3044
3044 Background: XL647 is an orally bioavailable small molecule inhibitor of multiple receptor tyrosine kinases involved in tumor cell growth, angiogenesis, and metastasis, including EGFR (erbB1), erbB2, VEGFR2/KDR, and EphB4. Methods: Patients (pts)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6bd755416104e21c147b5cb3e829124b
https://doi.org/10.1200/jco.2006.24.18_suppl.3044
Zobrazit plný text záznamu
9
A phase I dose-escalation and pharmacokinetic (PK) study of a novel multiple-targeted receptor tyrosine kinase (RTK) inhibitor, XL647, in patients with advanced solid malignancies
Autor: H. Keer, Joel M. Reid, S. Hutchison, Lorelei J. Hanson, Joanne Halsey, S. Lacy, Jill Piens, Branimir I. Sikic, Araba A. Adjei, Heather A. Wakelee
Publikováno v: Journal of Clinical Oncology. 23:3142-3142
3142 Background: XL647 is an orally bioavailable small molecule inhibitor of multiple RTKs involved in tumor cell growth, angiogenesis, and metastasis including EGFR (erbB1), erbB2, VEGFR-2, and Ep...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4fd3546b15ab4d4ef9782e9d0c97166f
https://doi.org/10.1200/jco.2005.23.16_suppl.3142
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje